感染

订阅

MedSci主页 / 所有栏目 / 感染

2019年美国皮肤病学会（AAD）年会：Bimekizumab治疗银屑病患者的长期有效性数据

2019-03-04 不详 网络

银屑病皮肤病bimekizumab
关注

全球生物制药公司UCB在中度至重度慢性斑块状银屑病患者中提供了bimekizumab的IIb期AB ABLE延伸研究的阳性数据，该研究显示，几乎所有BE ABLE 1试验中的应答者在完成60周的bimekizumab治疗后均保持完全或几乎彻底的皮肤病灶的清除。

全球生物制药公司UCB在中度至重度慢性斑块状银屑病患者中提供了bimekizumab的IIb期AB ABLE延伸研究的阳性数据，该研究显示，几乎所有BE ABLE 1试验中的应答者在完成60周的bimekizumab治疗后均保持完全或几乎彻底的皮肤病灶的清除。这项结果是迄今为止研究bimekizumab的最长期的数据，并进一步突出了该分子独特的双重作用机制的潜在价值：除了靶向IL-17A（驱动炎症过程的关键细胞因子）之外，它还能够有效地和选择性地中和IL-17F。

银屑病是一种慢性皮肤疾病，主要特色是在身上出现一块一块异常的皮肤。通常，这些块状皮肤异常会发红、发痒、以及脱屑。银屑病的症状轻自小片的病变、大至影响全身皮肤，皮肤的伤害可能会诱发伤口处发生干癣病变，称作寇柏纳现象。银屑病患者罹患干癣性关节炎、淋巴癌、心血管疾病、克罗恩氏症以及忧郁症的机会都较高。约有30%的银屑病患者患有银屑病性关节炎。


原始出处：

http://www.firstwordpharma.com/node/1627740#axzz5h9uGHFCc

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826121, encodeId=bc0c18261217a, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Aug 16 06:21:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943893, encodeId=71fb194389363, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Fri Dec 27 02:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912101, encodeId=404b191210170, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Aug 19 12:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362214, encodeId=e7d03622147e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Mar 07 20:58:52 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
    2019-08-16 一叶知秋

    #皮肤病#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1826121, encodeId=bc0c18261217a, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Aug 16 06:21:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943893, encodeId=71fb194389363, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Fri Dec 27 02:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912101, encodeId=404b191210170, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Aug 19 12:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362214, encodeId=e7d03622147e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Mar 07 20:58:52 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
    2019-12-27 naiwu77

    #MEK#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1826121, encodeId=bc0c18261217a, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Aug 16 06:21:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943893, encodeId=71fb194389363, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Fri Dec 27 02:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912101, encodeId=404b191210170, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Aug 19 12:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362214, encodeId=e7d03622147e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Mar 07 20:58:52 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
    2019-08-19 snf701207

    #mAb#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1826121, encodeId=bc0c18261217a, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Aug 16 06:21:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943893, encodeId=71fb194389363, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Fri Dec 27 02:21:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912101, encodeId=404b191210170, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Aug 19 12:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362214, encodeId=e7d03622147e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Mar 07 20:58:52 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
    2019-03-07 医者仁心5538

    学习了

    0

相关资讯

2019 AAD/NPF指南：银屑病伴意识和注意力合并症的管理的治疗

2019年2月，美国皮肤病学会(AAD)联合国家银屑病基金会(NPF)共同发布了银屑病伴意识和注意力合并症的管理的治疗指南，文章主要针对成人银屑病皮外表现主要包括共存疾病，精神疾病，社会心理健康以及生活质量等提出指导建议。

欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价

AbbVie今天宣布欧洲药品管理局（EMA）人用医药产品委员会（CHMP） 推荐将SKYRIZI（risankizumab）是一种研究性白细胞介素-23（IL-23）单抗，用于治疗成人患者的中度至重度斑块状银屑病。

JCEM：二甲双胍在银屑病糖尿病患者中的安全性分析

由此可见，二甲双胍可用于治疗糖尿病性银屑病患者，无需担心安全问题。

“寻常型银屑病”患者手部起皮疹伴破溃疼痛 罪魁祸首是…

60岁男性，“寻常型银屑病”病史40余年，长期自行口服MTX、氮芥、活血解毒丸（含砷），用量不规律。口腔出现肿物伴破溃，行病理检查示鳞状细胞癌，进行放化疗。2年前手部起皮疹伴破溃、疼痛。手部皮损诊断为何？

2019 AAD/NPF指南：应用生物制剂治疗银屑病

2019年2月，美国皮肤病学会(AAD)联合国家银屑病基金会(NPF)共同发布了生物制剂治疗银屑病指南，银屑病是一种慢性炎症性多系统疾病，该指南解决了应用生物制剂治疗银屑病的重要临床问题，并根据现有证据提供指导建议。

Cardiovasc Res：生物疗法有希望用于动脉粥样硬化的治疗。

最新研究发现，生物疗法可显着改善严重银屑病患者的冠状动脉斑块情况。